Compare JPMorgan Chase & Co (JPM) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Revvity Inc — how do they compare? JPMorgan Chase & Co trades at $333.45 (market cap $880.98B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: JPMorgan Chase & Co is far larger — about 51.9× Revvity Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.99%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Revvity Inc for 12 Days on average.
| JPM | RVTY | |
|---|---|---|
Market Cap | $880.98B | $16.98B |
Volume | 7,721,661 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $365.18 | $157.36 |
52-Week Low | $282.84 | $82.26 |
Typical Hold Time | 127 Days | 12 Days |
Enterprise Value | $1.82T | $19.30B |
Dividend Yield | 1.99% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $332.99, up 1.03% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to a projected $194.9B in 2026. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook: JPM offers value with solid profitability and analyst upside, but risks include geopolitical tensions and cybersecurity threats. The stock's bearish technicals near support at $327 suggest caution, though institutional buying and high ROE provide stability. Investors should weigh strong fundamentals against macroeconomic headwinds highlighted in recent news.
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
